Diamond Equity Weighs in on MAIA Biotechnology Q1 Earnings

Posted by Editorial Team on Mar 28th, 2025

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Free Report) – Equities researchers at Diamond Equity issued their Q1 2026 earnings estimates for MAIA Biotechnology in a research note issued to investors on Tuesday, March 25th. Diamond Equity analyst H. Diamond anticipates that the company will earn ($0.18) per share for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.30) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.69) EPS.

MAIA Biotechnology Price Performance

NYSEAMERICAN:MAIA opened at $1.63 on Wednesday. The company has a market cap of $42.64 million, a price-to-earnings ratio of -1.18 and a beta of 0.20. The business has a fifty day moving average of $1.85. MAIA Biotechnology has a 12-month low of $1.46 and a 12-month high of $5.99.

Hedge Funds Weigh In On MAIA Biotechnology

A number of large investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of MAIA Biotechnology during the third quarter worth $31,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology during the fourth quarter worth about $77,000. Finally, Geode Capital Management LLC boosted its position in MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after buying an additional 35,821 shares in the last quarter. 5.65% of the stock is currently owned by institutional investors and hedge funds.

MAIA Biotechnology Company Profile

(Get Free Report)

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.